Did You Know?

Editor’s Picks

Latest News

Arcutis Announces Top Line Results for Phase 2 Proof-of-Concept Clinical Trial Evaluating ARQ-151 as a Potential Topical Treatment for Atopic Dermatitis

- Consistent evidence of symptomatic improvement across endpoints and favorable tolerability - Higher dose demonstrated trend towards significance on primary...

Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker

CHARLOTTESVILLE, VA / ACCESSWIRE / December 16, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on...

error: Content is protected !!